- Home
- DTIL vs ANL Comparison
DTIL vs ANL Comparison
Compare DTIL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTIL | ANL |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 350.9M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | DTIL | ANL |
|---|---|---|
| Price | $4.70 | $9.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $60.00 | $16.00 |
| AVG Volume (30 Days) | 158.4K | ★ 218.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $0.88 |
| 52 Week High | $8.82 | $12.09 |
Technical Indicators
Market Signals| Indicator | DTIL | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 66.41 | 55.38 |
| Support Level | $4.66 | $1.37 |
| Resistance Level | $5.19 | $10.15 |
| Average True Range (ATR) | 0.28 | 0.92 |
| MACD | 0.10 | -0.33 |
| Stochastic Oscillator | 88.55 | 53.74 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.